UTHR at a glance
UNITED THERAPEUTICS Corp (UTHR, SEC CIK 1082554) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), UNITED THERAPEUTICS Corp (UTHR) reported revenue of $3.2 billion (up 10.6% from FY2024) and net income of $1.3 billion. Diluted EPS was $27.86.
- As of September 30, 2026, 40 institutional investment managers tracked by SignalX reported holding UNITED THERAPEUTICS Corp (UTHR) shares worth $10.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by MAHON PAUL A on November 19, 2026 of 440 shares at $554.73 per share.
- In the last 90 days, UTHR insiders reported 0 open-market purchases ($0) and 870 open-market sales ($343.3M) on Form 4, a net sale of $343.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.2B
- +10.6% vs prior year
- Insiders · 90 days
- 0 buys · 870 sells
- Net −$343.3M
- 13F holders
- 40 funds
- $10.2B · −1 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $832.5M, up from $799.5M YoY, a $33.0M increase
- Total Tyvaso $503.8M, up 5% YoY; Tyvaso DPI $378.5M best performer, Nebulized Tyvaso $125.3M, down 12%
- R&D expense $279.2M vs $127.5M YoY, driven by Thymmune acquisition and organ projects
- Cash and investments $3,535.7M at September 30, down $1,161.3M from December 31; operating cash flow $1,083.4M
- $3.0B share-repurchase authorization fully utilized; near-term growth expected from Tyvaso DPI, PH-ILD, ralinepag and IPF approval opportunities, with competition and pricing pressure headwinds
Risk Factors
- New regulatory risk: FDA’s September 2026 OAI classification for sole-source ScinoPharm could delay ralinepag approval beyond June 24, 2027
- Most material operational update: Yutrepia competition reduced Nebulized Tyvaso sales, with nine-month revenue down $81.5 million
- Legal risk: 340B contract-pharmacy policy remains subject to potential HRSA or state enforcement despite favorable appellate rulings
- Near-term reimbursement risk: Medicare Part D discounts increased to 10% initial-phase and 20% catastrophic-phase reductions
- Financial risk: Cash and investments declined 25% to $3,535.7 million after $3.0 billion share repurchases热在线精品
AI summary of the UTHR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 earnings release for the quarter ended September 30, 2026
- Detailed financial results and management commentary in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $832.5M, up 4%, led by Tyvaso DPI $378.5M, up 13%, and Orenitram $145.0M, up 11%
- Net income $258.6M, down 24%, as R&D surged 119% to $279.2M, primarily from Thymmune IPR&D and organ-development projects
Item 8.01: Other Events
- $2.0 billion share repurchase authorization approved, signaling substantial capital return to shareholders
- Program runs through October 21, 2027, providing flexibility on repurchase timing
Item EX-99.1: Item EX-99.1
- New $2 billion repurchase authorization available through October 21, 2027
- Capital-return capacity signals management confidence and prioritizes buybacks alongside long-term investment
Item 8.01: Other Events
- Liquidia settlement provides UTHR $330.4M, including $185M for past Yutrepia PH-ILD sales and $145.4M through April 2027
- Yutrepia must remove its PH-ILD indication, restricting Liquidia’s marketing, sales, payer access and related clinical-trial activity
Item EX-99.1: Item EX-99.1
- Liquidia owes UTC $330.4M total: $185M immediate damages plus $145.4M for future PH-ILD sales
- UTC pays Liquidia $10M to resolve one proceeding, making net stated cash consideration to UTC $320.4M
AI summaries of UTHR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for UTHR
Don't miss the next UTHR filing
- Alerts as it files. A push when UTHR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut UTHR, by share count.
- Ask anything. An AI agent that reads every UTHR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MAHON PAUL A | M | Nov 19, 2026 | 8,300 | $146.03 |
| MAHON PAUL A | Sell | Nov 19, 2026 | 440 | $554.73 |
| MAHON PAUL A | Sell | Nov 19, 2026 | 1,240 | $556.07 |
| MAHON PAUL A | Sell | Nov 19, 2026 | 523 | $557.46 |
| MAHON PAUL A | Sell | Nov 19, 2026 | 378 | $558.49 |
| MAHON PAUL A | Sell | Nov 19, 2026 | 400 | $559.50 |
| MAHON PAUL A | Sell | Nov 19, 2026 | 197 | $560.63 |
| MAHON PAUL A | Sell | Nov 19, 2026 | 300 | $561.78 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.9B | $3.2B |
| Gross Profit | - | $2.6B | $2.8B |
| Operating Income | - | $1.4B | $1.5B |
| Net Income | - | $1.2B | $1.3B |
| Gross Margin | - | 89.2% | 87.9% |
| Op. Margin | - | 47.9% | 46.9% |
| Net Margin | - | 41.5% | 41.9% |
| Balance Sheet | |||
| Total Assets | $7.2B | $7.4B | $7.9B |
| Equity | $6.0B | $6.4B | $7.1B |
| ROE | - | 18.5% | 18.8% |
| Per Share | |||
| EPS | - | $24.64 | $27.86 |
| Cash Flow | |||
| Operating CF | - | $1.3B | $1.6B |
| CapEx | - | $246.5M | $520.5M |
Source: XBRL data in UNITED THERAPEUTICS Corp (UTHR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate UTHR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 40 | $10.25B |
| Q2 2026 | 41 | $10.20B |
| Q1 2026 | 40 | $11.55B |
| Q4 2025 | 37 | $9.44B |
| Q3 2025 | 36 | $8.82B |
| Q2 2025 | 35 | $5.84B |
| Q1 2025 | 34 | $4.54B |
| Q4 2024 | 30 | $4.95B |
- Citadel Advisors LLC+623.8K (+205%)
- Invesco Ltd+333.2K (+70%)
- BlackRock+280.6K (+5%)
- State Street Corp+54.5K (+3%)
- Prudential Financial+41.1K (+245%)
- Franklin Resources−138.3K (-41%)
- AQR Capital Management−122.4K (-22%)
- Millennium Management−111.7K (-27%)
- T. Rowe Price Group−104.2K (-43%)
- Citigroup−81.7K (-31%)
- FMR LLC (Fidelity)−473.4K
- Blackstone Group−1.8K
- Marex Group plc−1.4K
- Equitable Holdings Inc−627
Source: 13F-HR filings on SEC EDGAR (aggregated from 293 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
UTHR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 9, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 4 | Oct 28, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
UTHR SEC filings: frequently asked questions
Are UTHR insiders buying or selling?
In the last 90 days, UNITED THERAPEUTICS Corp (UTHR) officers, directors and 10% owners reported no open-market purchases and 870 open-market sales worth $343.3 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold UTHR stock?
As of September 30, 2026, the largest UNITED THERAPEUTICS Corp (UTHR) holders among the 13F filers tracked by SignalX were BlackRock ($3.0 billion), State Street Corp ($1.1 billion), Vanguard Capital Management LLC ($1.0 billion), Vanguard Portfolio Management LLC ($1.0 billion), Renaissance Technologies LLC ($908.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was UTHR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), UNITED THERAPEUTICS Corp (UTHR) reported revenue of $3.2 billion (up 10.6% from FY2024) and net income of $1.3 billion. Diluted EPS was $27.86. The figures come from the XBRL data in the 10-K.
What did UTHR report in its latest 8-K?
UNITED THERAPEUTICS Corp (UTHR) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 earnings release for the quarter ended September 30, 2026.
What are the latest UTHR SEC filings?
UNITED THERAPEUTICS Corp (UTHR) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 19, 2026.
What is UTHR's SEC CIK number?
UNITED THERAPEUTICS Corp (UTHR)'s SEC Central Index Key (CIK) is 1082554. EDGAR lists every UTHR filing under that number.
Ask anything about UTHR
The research agent reads UTHR's filings, financials, insider trades and 13F holders, then answers with sources.